Encore Pharma | Biotech Hunter

About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct

Clinical Trials (7)

View all

Total Trials

7

As Lead Sponsor

6

As Collaborator

1

Total Enrollment

753

By Phase

PHASE1: 3PHASE3: 1PHASE2: 1PHASE2/PHASE3: 1PHASE4: 1

By Status

RECRUITING: 4UNKNOWN: 2COMPLETED: 1

Clinical Trials Pipeline7 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

2031

2032

2033

Today

NCT05537987

NCT06351527

NCT06363994

Hover over trial bars to see details

Recent Trials

NCT06530966Lead Sponsor

Phase I Study of ICP-332 in Healthy Subjects

PHASE1Recruiting

24 participants

Started: Jul 23, 2024 · Completed: Dec 25, 2024

NCT06363994Lead Sponsor

A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL

PHASE3Recruiting

476 participants

Started: May 29, 2024 · Completed: Jun 25, 2032

NCT06351527Lead Sponsor

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies

PHASE1Recruiting

78 participants

Started: Apr 23, 2024 · Completed: Oct 25, 2027

NCT05978739Lead Sponsor

Evaluating Different Doses of Orelabrutinib in MCL

PHASE2Recruiting

40 participants

Started: Aug 18, 2023 · Completed: May 25, 2025

NCT05607979Lead Sponsor

Restoring Tissue and Evaluating Novel Treatments for Efficacy in Wounds

PHASE2/PHASE3Completed

75 participants

Started: Dec 15, 2022 · Completed: May 1, 2024

View all 7 trials →